Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Pfizer invents and sells medicines and vaccines, and makes most of its money by patenting new drugs and selling them at high prices while it holds the exclusive rights.
Pfizer is one of the world's largest drugmakers. It discovers, tests, and sells medicines and vaccines — things like the COVID-19 vaccine it built with BioNTech, cancer drugs, and treatments for heart and inflammatory diseases. Its customers are mostly not you and me; they are insurers, governments, hospitals, and pharmacies that pay for the drugs a doctor prescribes. Pfizer's whole economic engine is the patent: a new medicine is protected by law for years, letting Pfizer charge a high price without generic competition, and when the patent expires the price collapses.
A drug company is basically a giant bet on research. Pfizer spends billions every year on scientists and clinical trials, knowing most experiments fail. The winners have to pay for the losers — one blockbuster can earn more than all the failures cost. That is why Pfizer hunts for big sellers, and why losing patent protection on a top drug is a cliff: sales can drop sharply almost overnight as cheap generics rush in. Pfizer got a huge, temporary windfall from the COVID vaccine and its antiviral pill. Revenue peaked around $100 billion in 2022, then fell back as the pandemic faded and several key patents expired. That cash pile funded a big acquisition spree, including the $43 billion purchase of Seagen, a cancer-drug specialist, to refill the pipeline. Like most big pharma, Pfizer also pays a substantial dividend, which keeps income-focused investors around.
In 1849, two cousins opened a small chemical shop in a red brick building in Brooklyn. Charles Pfizer knew chemistry and Charles Erhart was a confectioner, so they mixed medicine with something sweet to make it easier to swallow. Their first product treated intestinal worms, and the idea of making nasty medicine taste better was the seed of the whole company.
During World War I, the calcium citrate Pfizer needed to make citric acid got hard to find. So the company found a fungus that turned sugar into citric acid and built a business around that fermentation trick. That same skill later became the key to making penicillin in huge amounts, which was a much bigger deal than anyone saw coming.
Pfizer had stayed a private, family-run firm for decades, but by 1942 it sold shares to the public. That gave it money to grow and turned it into a company owned by many strangers instead of a few insiders.
Penicillin profits were fading, so Pfizer needed a new engine. It found oxytetracycline, an antibiotic of its own, and that discovery changed what the company was: less a chemical maker, more a drug company that hunts for new medicines in the lab.
In 1998 Pfizer launched Viagra, a pill for erectile dysfunction, and it became a cultural sensation. More importantly for the business, it became a steady, reliable stream of cash.
Pfizer joined forces with Warner-Lambert in 2000, folding the two into one giant. The combined company became the fastest-growing major drugmaker in the world, and the deal showed that buying other firms was now part of how Pfizer grew.
Pfizer acquired Wyeth in 2009, adding products that reached patients at every stage of life. The idea was to build a company whose medicines touched people from childhood to old age, so no single product had to carry the whole business.
Pfizer's partnership with BioNTech produced Comirnaty, the first authorized mRNA vaccine in the world. The vaccine brought in tens of billions and made Pfizer a household name again, the kind of fame it had not had since Viagra.
In 2023 Pfizer paid $43 billion for Seagen, putting cancer drugs at the center of its portfolio. The deal brought antibody-drug conjugate technology, a clever way to aim powerful drugs at tumors, plus drugs like Padcev and Adcetris. But it also loaded the company with a lot of debt.
Pfizer gave up on its own oral weight-loss drug danuglipron over safety worries. Instead it bought Metsera for $7 billion and licensed assets from YaoPharma to compete in obesity. The move pushed Pfizer away from leaning so hard on primary care and vaccines and toward specialized medicine, cancer and obesity.
The honest version: Pfizer is a mature giant with a thin pipeline of new blockbusters relative to its size, facing patent cliffs and price pressure from governments trying to control drug costs. Its edge is scale — the money and machinery to run huge trials and sell in nearly every country — but its weakness is that the next big cure is never guaranteed, and today's profits depend heavily on yesterday's inventions.
Saved answer · last researched 22 Oct 2026